(Photo Courtesy: www.atasigorta.az)
Key financial & performance highlights Q3 FY14-15 vis-a-vis Q3 FY13-14:
(Current year figures include the relevant results of Cipla's subsidiaries from the date they became subsidiary of the company and therefore the corresponding figures for the previous period are not comparable).
• Income from operations grew by 6.5% to Rs 2,765 cr, up from Rs 2,596 cr
• EBITDA grew by 18.5% to Rs 554 cr, up from Rs 467 cr
• Profit after tax grew by 15.3% to Rs 328 cr, up from Rs 284 cr
Profit & Loss Highlights:
• Material cost is at 35.8% of income from operations in Q3 FY14-15 as compared to 38.5% in Q3 FY13-14
• EBIDTA margin as % of income from operations increased by 200 bps at 20% in Q3 FY14-15 as compared to Q3 FY13-14
• Profit after tax increased by 15.3% to Rs 328 cr during Q3 FY14-15 as compared to Rs 284 cr during Q3 FY13-14
Performance Review:
Domestic business:
• Domestic sales grew by 14.2% to Rs 1,199 cr during Q3 FY14-15, up from Rs 1,050 cr during Q3 FY13-14
• The growth in domestic sales was largely on account of growth in Respiratory, Anti-infectives, Cardiac and Gastro Intestinal therapies
International business:
• Exports of formulations decreased by 6.2% to Rs 1,275 cr during Q3 FY14-15, down from Rs 1,360 cr during Q3 FY13-14.
• Exports of APIs declined to Rs 151 cr during Q3 FY14-15, from Rs 158 cr during Q3 FY13-14.
